Universal Beteiligungs und Servicegesellschaft mbH Makes New $127.22 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 178,590 shares of the biopharmaceutical company's stock, valued at approximately $127,215,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.16% of Regeneron Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of REGN. OLD Second National Bank of Aurora boosted its stake in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock worth $2,025,000 after acquiring an additional 15 shares during the last quarter. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the last quarter. TD Private Client Wealth LLC lifted its position in shares of Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 15 shares during the last quarter. Manchester Capital Management LLC raised its position in Regeneron Pharmaceuticals by 12.6% during the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 18 shares in the last quarter. Finally, Financial Perspectives Inc boosted its position in Regeneron Pharmaceuticals by 10.9% during the 4th quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company's stock valued at $137,000 after acquiring an additional 19 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 2.3%

Regeneron Pharmaceuticals stock traded up $13.54 during trading hours on Thursday, hitting $605.39. 756,649 shares of the stock traded hands, compared to its average volume of 804,172. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market cap of $65.36 billion, a PE ratio of 15.81, a PEG ratio of 2.34 and a beta of 0.43. The firm's 50-day moving average price is $588.18 and its two-hundred day moving average price is $671.20. Regeneron Pharmaceuticals, Inc. has a one year low of $520.50 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.55 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.58%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Analyst Ratings Changes

Several analysts have recently commented on REGN shares. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. TD Cowen decreased their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Robert W. Baird reduced their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. Finally, Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $890.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.